Stephen Strickland, MD, MSCI

For patients with the fast-moving blood cancer acute myeloid leukemia (AML), the wonders of chimeric antigen receptor (CAR) T-cell therapy have been off limits. But that could be changing, after data recently presented at the American Association for Cancer Research […]

In some blood cancers, chimeric antigen receptor (CAR) T-cell therapy has been lifesaving. These treatments are engineered with patients’ own T cells to express a synthetic receptor, or CAR, that binds to antigens to set loose a powerful immune response.